Ocugen, Inc. OCGN R3KPHARMA

Q: What is the current share price of Ocugen, Inc. (OCGN)?

As of 2026-09-19 21:16 PDT, Ocugen, Inc. (OCGN) trades at $1.33 on NasdaqCM. Its 52-week range is $1.00 to $2.48.

Q: What is the market capitalisation of OCGN?

Ocugen, Inc. (OCGN) has a market capitalisation of $451.02M on NasdaqCM.

Q: What is the P/E ratio of OCGN?

OCGN trades at a trailing price-to-earnings (P/E) ratio of -5.12. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -21.63.

Q: Is OCGN a good stock to buy?

This page provides a data-driven analysis of Ocugen, Inc. (OCGN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.ocugen.com

Company Profile ↓

$1.33

+29.13% 1Y

Mkt Cap$451.02M

P/E-5.12

P/B-21.63

52W High$2.48

52W Low$1.00

Book Value$-0.05

EPS (TTM)$-0.26

Company Overview

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Recent Developments

Dec 2025 Revenue of $4.41M (+8.8% YoY); net profit $-67.85M.
Trailing 12 Months Year-on-year growth — revenue +8.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	-
1 Year:	8.40%

Stock Price Performance

1 Year:	+29.13%
6 Months:	-19.88%
3 Months:	+5.56%
1 Month:	+3.91%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 22% of range

$1.00 $2.48

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)47.74 · Neutral

Price Performance

1M+3.91%

3M+5.56%

6M-19.88%

1Y+29.13%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

Trading 46.4% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-5.12

Industry PE

24.83

Forward P/E

-4.99

PEG Ratio

Book Value

$-0.05

Price to Book

-21.63

P/S

78.47

EV/EBITDA

-5.02

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

Revenue (YoY)

8.40%

Earnings (YoY)

Profitability & Returns

ROCE

ROE

ROA

-48.44%

Profit Margin

0.00%

Op Margin

Gross Margin

0.00%

EPS (Latest Qtr)

$-0.07

EPS (TTM)

$-0.26

Balance Sheet & Liquidity

Debt/Equity

5.74

Quick Ratio

0.75

Current Ratio

0.80

Debt

$87.99M

Total Assets

$124.21M

Current Assets

$38.55M

Working Capital

$1.30M

Ownership

Promoter Holding

1.54%

Chg in Prom Hold

-0.14%

FII / Inst Holding

43.31%

Chg in FII Hold

0.01%

Financial Snapshot

Enterprise Value

$451.02M

Total Revenue (TTM)

$4.58M

EBITDA

$-67.17M

Free Cash Flow

$-1.97M

Operating Cash Flow

$-60.87M

Shares Outstanding

339.11M

Gross Margin

0.00%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	OCGN Ocugen, Inc. R3KPHARMA	1.33	-5.12	$451.02M	0.00%	-	-	-	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	-	-	-	-	-	-	-	-	500.00K	643.00K	466.00K	443.00K	485.00K	3.70M	1.01M	1.14M	1.14M	1.48M	1.37M	1.75M	-193.00K	1.53M	1.49M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15.98M	15.17M	19.38M	16.80M	19.37M	-
Operating Income	-5.17M	-6.01M	-14.94M	-7.87M	-7.59M	-8.04M	-7.80M	-7.96M	-6.65M	-6.83M	-6.37M	-5.71M	-6.09M	-7.28M	-2.40M	-4.84M	-2.33M	-2.71M	-3.93M	-3.37M	-10.18M	-7.06M	-25.61M	-10.79M	-19.03M	-21.58M	-25.11M	-18.04M	-23.54M	-12.43M	-12.22M	-15.45M	-13.25M	-14.50M	-13.79M	-17.62M	-17.00M	-17.84M	-16.44M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-13.50M	-12.55M	-17.79M	-16.37M	-17.27M	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.26M	-	1.31M	1.33M	1.32M	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-15.35M	-14.74M	-20.05M	-17.71M	-19.18M	-
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-3.44M	-8.30M	-11.97M	-7.96M	-7.63M	-8.08M	-7.92M	-8.04M	-9.31M	-7.08M	-6.54M	-6.00M	-5.04M	-5.29M	-1.93M	-6.31M	-3.54M	-22.77M	-3.94M	-3.61M	-10.47M	-7.08M	-25.95M	-10.76M	-19.02M	-21.48M	-23.91M	-17.33M	-23.07M	-11.72M	-11.92M	-15.28M	-12.97M	-15.35M	-14.74M	-20.05M	-17.71M	-19.18M	-24.88M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-0.23	-	-	-0.24	-	-	-	-	-0.19	-0.07	-0.04	-0.13	-0.05	-0.09	-0.10	-0.11	-0.08	-0.10	-0.05	-0.05	-0.04	-	-0.05	-0.05	-0.06	-0.06	-0.06	-0.07
R&D Expense	-3.37M	4.67M	13.24M	5.76M	5.86M	5.85M	5.59M	5.79M	4.88M	4.50M	4.21M	3.49M	3.29M	4.46M	1.56M	3.79M	446.00K	1.31M	1.65M	-	-	-	-	-	-	-	-	-	-	-	6.83M	8.90M	8.11M	9.53M	8.40M	11.15M	-	11.26M	10.69M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	0	0	0	0	0	0	43.00K	-	2.49M	6.04M	4.05M	4.41M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	91.56M	71.57M	58.81M	67.33M
Operating Income	-32.66M	-31.82M	-30.31M	-24.95M	-16.14M	-14.16M	-21.29M	-	-89.07M	-65.53M	-54.76M	-62.92M
EBITDA	-	-	-	-	-	-	-	-	-88.59M	-64.83M	-51.40M	-60.27M
Interest Expense	-	-	-	-	-	-	-	79.00K	-	-	688.00K	5.19M
Pretax Income	-	-	-	-	-	-	-	-	-86.80M	-63.08M	-54.05M	-67.85M
Tax Provision	-	-	-	-	-	-	-	-52.00K	0	-	-	-
Net Income	-22.79M	-32.02M	-16.21M	-26.41M	-18.22M	-20.24M	-21.82M	-	-86.80M	-63.08M	-54.05M	-67.85M
Diluted EPS	-	-2.42	-2.18	-0.99	-0.79	-1.46	-0.31	-	-0.38	-0.26	-0.20	-0.23
R&D Expense	26.04M	23.24M	21.58M	15.57M	10.32M	8.09M	-	-	-	39.57M	32.13M	39.75M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	65.50M	36.79M	36.08M	11.04M	2.45M	16.81M	27.38M	-	141.73M	130.09M	116.24M	108.63M	96.30M	88.98M	74.69M	64.55M	82.44M	43.52M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	98.49M	-	-	-	42.97M	61.68M	24.34M
Cash & Equivalents	8.73M	58.53M	30.91M	31.91M	7.08M	1.63M	7.44M	24.04M	-	129.77M	115.00M	101.60M	77.56M	68.26M	70.58M	53.48M	39.46M	58.51M	18.57M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	11.29M	8.59M	22.51M	22.30M	15.16M	5.79M	5.83M	-	16.21M	23.61M	30.55M	34.65M	31.40M	29.73M	24.89M	23.98M	52.81M	55.68M
Current Liabilities	-	7.60M	6.36M	5.17M	3.81M	14.11M	4.54M	3.61M	-	13.30M	17.96M	24.52M	28.53M	26.58M	24.50M	19.73M	17.09M	21.59M	23.04M
Long Term Debt	-	-	-	-	-	1.02M	1.07M	1.82M	-	1.73M	1.75M	2.27M	2.29M	1.06M	1.47M	1.50M	2.80M	27.34M	27.54M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	6.37M	-	-	-	6.94M	32.50M	33.14M
Total Equity	-75.55M	54.21M	28.20M	13.57M	4.43M	-12.71M	11.02M	21.55M	-	125.52M	106.48M	85.69M	73.98M	64.90M	59.24M	49.80M	40.56M	29.63M	-12.17M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	221.72M	-	-	-	256.69M	291.49M	312.50M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	-23.02M	-11.63M	-16.89M	-14.71M	-	-60.08M	-62.05M	-42.14M	-56.96M
Investing Cash Flow	-	-	-	-1.23M	-77.41K	-2.36M	-307.00K	-	-16.97M	3.08M	-3.38M	-311.00K
Financing Cash Flow	-	-	-	-577.00K	7.18M	25.07M	31.61M	-	59.48M	20.88M	64.86M	17.33M
Capital Expenditure	-3.32M	-1.95M	-320.00K	-276.00K	-77.41K	-30.00K	-307.00K	-	-4.46M	-10.48M	-3.38M	-185.00K
Free Cash Flow	-	-	-	-23.30M	-11.71M	-16.92M	-15.02M	-	-64.54M	-72.53M	-45.53M	-57.15M
Net Change in Cash	-	-	-	-	-	-	-	-	-17.57M	-38.10M	19.33M	-39.95M
Share Buybacks	-	-	-	-	0	48.00K	0	0	-	-	-	-

Ratios (Annual)

Figures in %.

Metric	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-	-49,500.0%	-	-3,580.0%	-1,085.7%	-1,350.4%	-1,425.7%
Net Margin %	-	-	-	-	-	-	-50,748.8%	-	-3,488.9%	-1,045.0%	-1,333.0%	-1,537.4%
ROE %	-42.0%	-113.6%	-119.5%	-595.6%	143.4%	-183.7%	-101.3%	-	-117.3%	-155.5%	-182.4%	557.7%
ROCE %	-56.4%	-104.6%	-98.1%	-345.1%	138.5%	-115.5%	-89.6%	-	-111.2%	-138.1%	-90.0%	-307.3%

Shareholding Pattern

Insiders

1.54%

Institutions

43.31%

Public Float

43.99%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	7.96%	27.00M	$28.62M
2	State Street Corporation	6.33%	21.47M	$22.76M
3	Vanguard Capital Management LLC	4.24%	14.37M	$15.23M
4	Millennium Management Llc	4.11%	13.94M	$14.78M
5	Geode Capital Management, LLC	2.62%	8.87M	$9.40M
6	RTW Investments LP	1.97%	6.67M	$7.07M
7	UBS Group AG	1.53%	5.18M	$5.49M
8	Ikarian Capital, LLC	1.17%	3.96M	$4.20M
9	GMT Capital Corp	1.03%	3.51M	$3.72M
10	Marshall Wace LLP	1.01%	3.41M	$3.61M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for OCGN

Google News Sat, 05 Sep 2026

Ocugen Stock Price Forecast. Should You Buy OCGN? - StockInvest.us

<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE96aVprQ0NnRDZZbXhJSURDWDhMR1BtUnVwdDFuQnJUTEVfanNlNFE2cXZyYmpxMlNZNUhuUmhqdVRSQXhSVjN0VQ?oc=5" target="_blank">Ocugen Stock Price Forecast. Should You Buy OCGN?</a>  <fon…

Google News Wed, 24 Jun 2026

Ocugen (OCGN) Stock Draws Fresh Price Target Split After Cautious Analyst View - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPZkZEMHNDQ0JmTnZmR1c4dnFtRUloQzhLNkFxclh2OWR2Y21MMnhoMWcyUjY0UEN4dFQwamMzcG1wMVp5blprWHl0MU1mSzQxdFpsVC1qRVhnQnh3MnlTYmtPRzBncjBkaGZVV2kycVZsVG5KZjBjNmgyNXdySS03Uk40bVZibWxMMFlsQn…

Google News hu, 05 Mar 2026

Why Did OCGN Stock Rise Today? - Stocktwits

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQTGF3WGtIcWhESzZIT0RxeEoydzN5VDVuVWJKa1MxSFJZQnluUU1BOENubFdUeGZYd2xsMlZFVUJIWWdfeXFPWFREWXVfZ0JPRTVvSTFTM29wZjlmOXowRmszMTN3LThoN29tTHBScmNWRW5ocGdkREp2Tno4QVdsQ0hQMW1xWVFoZTR3R1…

Google News ue, 23 Jun 2026

$OCGN stock is up 7% today. Here's what we see in our data. - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPS1ptdndlR1dpb0FZZkFVR3Jrc29jV0JUQzJrUFpCZUZydkdUaTNBX2N5ODYtWGVYRk9QQ3JKbkp6X1VOM1QwbVBVbGp1M0pPaHR5MGNLazdSekxJUjYwR3lJTVoyRmJHZ2NJZ0ptamNKMERYTnRtQ3haUDZNNkN2eE5KWlA0Q3JIU05Xcn…

Google News Wed, 29 Jul 2026

BlackRock (OCGN holder) discloses 8.0% beneficial stake in Ocugen common stock - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNZGpJY2pKNkJ4ckl1SWF1XzNidXFhbDVBbmxsT3B2SGpjWHlUWmV6Q0h0U3FNTGpZU0Y5RUlycHdDbHNSVFBQRkVqMUU3ZGFLT3lWQ0pmVVMweFhaaTEtY1JvQ3BzempkOXV1a2ZtOEZwYXlJbHRwMlU1bG5hRmdZLUFBUnFOODN4SHRoMH…

Google News Wed, 03 Jun 2026

Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data? - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxQRWlEVEVQc1pPdXYwM25YV3hDdVMzUUhZaUpNTDBvbGxFQndoeUNDd1NxVXdocEJFN0FjalUzS1RpUzhjWTdpZFVZRWt4dXZ1WDhjNjVzSVhTNC1UYVloT1ZXVUdEcmY1WndXXzZQZTMtVHdmOGRubGM2YllOMHlfVXdQZkN3aTNWejJkeW…

OCGN — Frequently Asked Questions

What is the current share price of Ocugen, Inc. (OCGN)?

As of 2026-09-19 21:16 PDT, Ocugen, Inc. (OCGN) trades at $1.33 on NasdaqCM. Its 52-week range is $1.00 to $2.48.

What is the market capitalisation of OCGN?

Ocugen, Inc. (OCGN) has a market capitalisation of $451.02M on NasdaqCM.

What is the P/E ratio of OCGN?

OCGN trades at a trailing price-to-earnings (P/E) ratio of -5.12. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -21.63.

Is OCGN a good stock to buy?

This page provides a data-driven analysis of Ocugen, Inc. (OCGN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Ocugen, Inc. OCGN R3KPHARMA

Company Overview

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Ocugen Stock Price Forecast. Should You Buy OCGN? - StockInvest.us

Ocugen (OCGN) Stock Draws Fresh Price Target Split After Cautious Analyst View - finance.yahoo.com

Why Did OCGN Stock Rise Today? - Stocktwits

$OCGN stock is up 7% today. Here's what we see in our data. - Quiver Quantitative

BlackRock (OCGN holder) discloses 8.0% beneficial stake in Ocugen common stock - Stock Titan

Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data? - finance.yahoo.com

OCGN — Frequently Asked Questions

What is the current share price of Ocugen, Inc. (OCGN)?

What is the market capitalisation of OCGN?

What is the P/E ratio of OCGN?

Is OCGN a good stock to buy?

Explore More